A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Trial Profile

A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Daclatasvir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jan 2011 Actual end date (Sep 2010 ) added as reported by ClinicalTrials.gov.
    • 02 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top